Novo Nordisk A/S (OCSE:NOVO B) Tax Provision : kr-22,579 Mil (TTM As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Novo Nordisk A/S Tax Provision?

Novo Nordisk A/S's tax provision for the three months ended in Mar. 2024 was kr-6,511 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was kr-22,579 Mil.

Novo Nordisk A/S Tax Provision Historical Data

The historical data trend for Novo Nordisk A/S's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Tax Provision Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-9,602.00

-10,992.00

-11,323.00

-13,537.00

-20,991.00

Novo Nordisk A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															-4,923.00	-4,826.00	-5,585.00	-5,657.00	-6,511.00

Novo Nordisk A/S Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-22,579 Mil.

Novo Nordisk A/S (OCSE:NOVO B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OCSE:NOVO B) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (OCSE:NOVO B) Headlines

No Headlines